Furthermore, breast cancer is typically associated with a comparatively good prognosis, especially for hormone-receptor positive disease, the subtype associated with MHT administration.12 Many people have limited understanding of the variability of disease-specific fatality for different cancer types: it may thus be of value to communicate the likelihood of dying from breast cancer as distinct from the likelihood of developing the disease. Here, NR4A1 is linked to breast carcinoma.